Advertisement


Alice T. Shaw, MD, PhD, on ALK, Crizotinib, and Alectinib

2015 IASLC World Conference on Lung Cancer

Advertisement

Alice T. Shaw, MD, PhD, of Massachusetts General Hospital, summarizes efficacy and safety data from studies on crizotinib, brigatinib, and alectinib for ALK-positive non–small cell lung cancer (ORAL 33.03, 33.06, 33.07).



Related Videos

Lung Cancer

Naiyer A. Rizvi, MD, on Immune Checkpoint Inhibitors

Naiyer A. Rizvi, MD, of Columbia University, offers an update on immune checkpoint inhibitors in non–small cell lung cancer: what’s new and what’s next.

Lung Cancer

Howard Jack West, MD, on New Kinase Targets for Treating Advanced NSCLC

Howard Jack West, MD, of the Swedish Cancer Institute, summarizes three important papers: anlotinib as third-line treatment for refractory advanced non–small cell lung cancer; the EGFR exon 20 mutation as a prognostic/predictive biomarker; and EGFR exon 18 mutations as molecular predictors of sensitivity to afatinib or neratinib (Abstracts ORAL 3.01, 3.02, and 3.03).

Lung Cancer

Jennifer King, PhD: Scientific Perspectives From the Lung Cancer Alliance

Jennifer King, PhD, of the Lung Cancer Alliance, gives her perspective on major themes of this year’s meeting: the stigma of lung cancer, the changing face of who is affected, early detection, and advances in immunotherapy.

Lung Cancer

Roy S. Herbst, MD, PhD, on Results From SWOG S0819

Roy S. Herbst, MD, PhD, of the Smilow Cancer Hospital at Yale Cancer Center, discusses his findings of a phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in advanced non–small cell lung cancer (Abstract PLEN04.01).

Lung Cancer

Karen Kelly, MD, on PD-1 Axis Inhibition and the Treatment of Advanced Disease

Karen Kelly, MD, of the University of California, Davis, summarizes three important papers on NSCLC: expression as a predictive biomarker; pembrolizumab, immune-mediated adverse events, and corticosteroid use; and an evaluation of disease-related symptoms in patients treated with nivolumab or docetaxel (Abstracts ORAL 31.01, 31.02, and 31.03).

Advertisement

Advertisement




Advertisement